[VIRTUAL] Relevance of Alternative Anti-Androgen Therapy for Castration-Resistant Prostate Cancer After Combined Androgen Blockade: A Prospective Observational Study of OCCU-CRPC Cohort

[VIRTUAL] Pembrolizumab (Pembro) Plus Olaparib in Patients With Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer (mCRPC): Updated Results From KEYNOTE-365 Cohort A With a Minimum of 11 Months of Follow-Up for All Patients

[VIRTUAL] Avelumab first-line maintenance for advanced urothelial carcinoma: analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial

[VIRTUAL] Prostate-Specific Antigen Kinetics in Patients With Advanced Prostate Cancer Treated With Apalutamide: Results from the TITAN and SPARTAN Studies

[VIRTUAL] Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer Patients Who Received Prior Antiandrogen Therapy: Post Hoc Analysis of ARCHES

[VIRTUAL] Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: transcriptomic data from patients receiving placebo on a randomized phase 3 trial (PROTECT)

[VIRTUAL] Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: analysis of 18F-DCFPyL uptake in possible extra-pelvic oligometastases

[VIRTUAL] Phase III Trial of Intravesical Nadofaragene Firadenovec in Patients with High-Grade, BCG-Unresponsive, Non-muscle Invasive Bladder Cancer: Two Year Follow-up in the Ta/T1 Cohort

[VIRTUAL] Efficacy of physician's choice of enzalutamide or abiraterone in the control arm of PROfound

[VIRTUAL] Impact of darolutamide on local symptoms in patients with nonmetastatic castration-resistant prostate cancer

[VIRTUAL] Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance: ENACT

[VIRTUAL] NAXIVA - A phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer with venous invasion: Translational results

[VIRTUAL] Anti-adenoviral Antibody Levels Predict Nadofaragene Firadenovec Response in BCG-unresponsive NMIBC: Results from a Phase 3 Trial

[VIRTUAL] Phase 2/3 clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in-situ (CIS) patients.

[VIRTUAL] Estimating recurrence-free survival of non-muscle invasive bladder cancer after intravesical therapy: A clinical-based recursive partition analysis